Study of STP938 (Dencatistat) in Advanced Solid Tumours
ConditionSolid Tumor
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorStep Pharma, SAS
About this trial
The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy.
The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.
Eligibility criteria
Qualifiers
Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.
Male or female aged ≥ 18 years.
Advanced disease not curable by available therapies and requires systemic therapy.
Histologically confirmed diagnosis of eligible cancer type.
Disqualifiers
Pregnant or breastfeeding females and women of childbearing potential or males unwilling to comply with contraception requirements.
Known active or symptomatic CNS metastases, carcinomatous meningitis, leptomeningeal disease or a history of spinal cord compression
Active malignancy within 2 years of study enrollment
Prior radiation within 2 weeks of start of therapy.
Trial design
Treatments tested in this trial
- STP938
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov